Alendronate therapy may be effective in the prevention of bone loss around titanium implants inserted in estrogen-deficient rats

Journal of Periodontology

Volumn 76, Issue 1, 2005, Pages 107-114

  Duarte, Poliana Mendes ^a   de Vasconcelos Gurgel, Bruno César ^a   Sallum, Antonio Wilson ^a   Nogueira Filho, Getúlio Rocha ^a   Sallum, Enilson Antonio ^a   Nociti Jr , Francisco Humberto ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Alendronate therapeutic use; Animal studies; Bone and bones; Dental implants; Estradiol therapeutic use; Estrogen deficiency; Titanium; Wound healing

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ESTRADIOL; ESTROGEN; TITANIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; DATA ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; ENZYME ANALYSIS; ESTROGEN DEFICIENCY; FEMALE; HEALING; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; RAT; RAT STRAIN; TOOTH IMPLANTATION; TOOTH PROSTHESIS;

ALENDRONATE; ALVEOLAR BONE LOSS; ANIMALS; BONE DENSITY; DENTAL ALLOYS; DENTAL IMPLANTATION, ENDOSSEOUS; DENTAL IMPLANTS; ESTRADIOL; ESTROGENS; FEMALE; OSSEOINTEGRATION; OVARIECTOMY; RATS; RATS, WISTAR; TITANIUM;

EID: 15944402065     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.1.107     Document Type: Article

References (38)

1. Brånemark PI. Osseointegration and its experimental background. J Prosthet Dent 1983;50:390-410.
2. Zarb GA, Schmitt A. The longitudinal clinical effectiveness of osseointegrated dental implants: The Toronto study. Part II: The prosthetic results. J Prosthet Dent 1990; 64:53-61.
3. Puleo DA, Nanci A. Understanding and controlling the bone-implants interface. Biomaterials 1999;20:2311-2321.
4. Harrison JE. Osteoporosis. In: Tam CS, Heersche JNM, Murray TM, eds. Metabolic Bone Diseases: Cellular and Tissue Mechanisms. Boca Raton, FL: CRC Press; 1989: 240-267.
5. Dao TTT, Anderson JD, Zarb GA. Is osteoporosis a risk factor for osseointegration of dental implants? Int J Oral Maxillofac Implants 1993;8:137-144.
6. Yamazaki M, Shirota T, Tokugawa Y, et al. Bone reactions to titanium screw implants in ovariectomized animals. Oral Surg Oral Med Oral Pathol 1999;87:411-418.
7. Pan J, Shirota T, Ohno K, Mich K. Effect of ovariectomy on bone remodeling adjacent to hydroxyapatite-coated implants in the tibia of mature rats. J Oral Maxillofac Surg 2000;58:877-882.
8. Duarte PM, César-Neto JB, Gonçalves PF, Sallum EA, Nociti FH Jr. Estrogen deficiency affects bone healing around titanium implants. A histometric study in rats. Implant Dent 2003;12:340-345.
9. Nociti FH Jr, Sallum AW, Sallum EA, Duarte PM. Effect of estrogen replacement and calcitonin therapies on bone around titanium implants placed in ovariectomized rats: A histometric study. Int J Oral Maxillofac Implants 2002;17:786-92.
10. Duarte PM, Cesar-Neto JB, Sallum AW, Sallum EA, Nociti FH Jr. Effect of estrogen and calcitonin therapies on bone density in a lateral area adjacent to implants placed in the tibiae of ovariectomized rats. J Periodontol 2003;74:1618-1624.
11. Dempster DW, Birchman R, Xu R, Lindsay R, Shen V. Temporal changes in cancellous bone structure of rats immediately after ovariectomy. Bone 1995;16:157-161.
12. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-822.
13. Regan MM, Emond SK, Attardo, MJ, Parker RA, Greenspan SL. Why do older women discontinue hormone replacement therapy? J Womens Health Gend Based Med 2001; 10:343-350.
14. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-388.
15. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
16. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-349.
17. Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991;19:926-932.
18. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000;22:1433-1442.
19. Wronski TJ, Schenck PA, Cintron M, Walsh CC. Effect of body weight on osteopenia in ovariectomized rats. Calcif Tissue Int 1987;40:155-159.
20. Vaananen HK, Harkonen PL. Estrogen and bone metabolism. Maturitas 1996;23(Suppl.):S65-S69.
21. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev 1994;15:275-300.
22. Pacifici R. Is there a causal role for IL-1 in postmenopausal bone loss? Calcif Tissue Int 1992;50:295-299.
23. Girasole G, Passeri G, Pedrazzoni M, Giuliani N, Passeri M. Interleukin-6: A pathogenetic role in the postmenopausal osteoporosis? Acta Biomed Ateneo Parmense 1995;66: 125-138.
24. Lindberg MK, Erlandsson M, Alatalo SL, et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. J Endocrinol 2001; 171:425-433.
25. Watts NB. Therapies to improve bone mineral density and reduce the risk of fracture: Clinical trial results. J Reprod Med 2002;47:82-92.
26. Wronski TJ, Dann LM, Qi H, Yen C-F. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calcif Tissue Int 1993;53:210-216.
27. Sims NA, Morris HA, Moore RJ, Durbridge TC. Estradiol treatment transiently increases trabecular bone volume in ovariectomized rats. Bone 1996;19:455-461.
28. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139: 1329-1337.
29. Simon JA, Mack CJ. Counseling patients who elect to discontinue hormone therapy. Int J Fertil Womens Med 2003;48:111-116.
30. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 2001;12:385-390.
31. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Frits PC. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73: 813-822.
32. Uusi-Rasi K, Kannus P, Cheng S, et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial. Bone 2003;33:132-143.
33. Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants 2003;18:218-223.
34. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-883.
35. Fleisch MH. Bisphophonates-history and experimental basis. Bone 1987;8:S23-S28.
36. Rossini M, Gatti D, Zamberlan N, Braga V, Dorrizi R, Adami S. Long-term effect of treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Mineral Res 1994;11:1833-1837.
37. Sones AD, Wolinsky LE, Kratochvil FJ. Osteoporosis and mandibular bone resorption in the Sprague Dawley rat. Calcif Tissue Int 1986;39:267-270.
38. Weiss RE, Gorn A, Dux S, Nimmi M. Influence of high protein diets on cartilage and bone formation in rats. J Nutr 1981;111:804-816.